Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part III. Management of Advanced Differentiated Thyroid Cancers - Chapter 3.Radioactive Iodine Therapy in Advanced Thyroid Cancer 2024
10.11106/ijt.2024.17.1.153
- Author:
Keunyoung KIM
1
;
Chae Moon HONG
;
Ho-Cheol KANG
;
Sun Wook KIM
;
Dong Gyu NA
;
Sohyun PARK
;
Young Joo PARK
;
Ji-In BANG
;
Youngduk SEO
;
Young Shin SONG
;
Sang-Woo LEE
;
Eun Kyung LEE
;
Dong-Jun LIM
;
Ari CHONG
;
Yun Jae CHUNG
;
So Won OH
;
Author Information
1. Department of Nuclear Medicine, Pusan National University Hospital, Busan, Korea
- Publication Type:REVIEW ARTICLES
- From:International Journal of Thyroidology
2024;17(1):153-167
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Radioactive iodine (RAI) therapy can effectively eliminate persistent or recurrent disease in patients with advanced differentiated thyroid cancer (DTC), potentially improving progression-free, disease-specific, and overall survival rates. Repeated administration of RAI along with thyroid-stimulating hormone (TSH) suppression is the mainstay of treatment for patients with distant metastases. Remarkably, one in three patients with distant metastases can be cured using RAI therapy and experience a near-normal life expectancy. Patients with elevated serum thyroglobulin and a negative post-RAI scan may be considered for empiric RAI therapy in the absence of structurally evident disease. However, in some patients, the iodine uptake capacity of advanced lesions decreases over time, potentially resulting in RAI-refractory disease. RAI-administered dose can be either empirically fixed high activities or dosimetry-based individualized activities for treatment of known diseases. The preparation method (levothyroxine withdrawal vs. recombinant human TSH administration) should be individualized for each patient.RAI therapy is a reasonable and safe treatment for patients with advanced DTC. Despite the risk of radiation exposure, administration of low-activity RAI has not been associated with an increased risk of a secondary primary cancer (SPM), leukemia, infertility, adverse pregnancy outcomes, etc. However, depending on the cumulative dose, there is a risk of acute or delayed-onset adverse effects including salivary gland damage, dental caries, nasolacrimal duct obstruction, and SPM. Therefore, as with any treatment, the expected benefit must justify the use of RAI in patients with advanced DTC.
